共 10 条
[1]
Chest[P]. WALTERS III GUY A;TOBIN JR AVIS EDWARD.中国专利:USD416144S,1999-11-09
[2]
The influenceof polymorphism at position16 of theβ2-adrenoceptor on the development of tolerance toβ-agonist. TaylorDR,HancoxRJ,McRaeW,et al. Journal of Asthma . 2000
[3]
Effectof early vs late intervention with inhaled corticosteroidsin asthma. SelroosO,PietinalhoA,LofroosAB,et al. Chest . 1995
[4]
Effects offormoterol and budesonide onGM-CSF andIL-8secretion by triggered human bronchial epithelialcells. KornSH,JerreA,BrattsandR. European Respiratory Journal . 2001
[5]
Effect of inhaled formoterol and budesonide onexacerbations of asthma. PauwelsRA,LofdahlCG,PostmaDS,et al. The New England Journal of Medicine . 1997
[6]
Molecular mechanisms ofcorticosteroid actions. AdcockIM,ItoK. MonaldiArchChestDis . 2000
[7]
Ligand-independent activation of the glucocorticoid receptorbyβ2-adrenergic receptor agonists in primary humanlung fibroblasts and vascular smooth muscle cells. EickelbergO,RothM,LorxR,et al. Journal of Biochemistry . 1999
[8]
Additive anti-inflammatory effect of formoterol andbudesonide on human lung fibroblasts. SpoelstraFM,PostmaDS,HovengaH,et al. Thorax . 2002
[9]
Comparison of the systemic effects of fluticasonepropionate and budesonide given by dry powderinhaler in healthy and asthmatic subjects. HarrisonTW,WisniewskiA,HonourJ,et al. Thorax . 2001
[10]
Fluticasone and salmeterol downregulate in vitrofibroblast proliferation andICAM-1 orH-CAMexpression. SilvestriM,FregoneseL,SabatiniF,et al. European Respiratory Journal . 2001